cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intellia Therapeutics Inc
123 own
42 watching
Current Price
$25.17
$0.02
(0.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,170.76M
52-Week High
52-Week High
46.50000
52-Week Low
52-Week Low
19.37000
Average Volume
Average Volume
0.97M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,170.76M
icon52-Week High46.50000
icon52-Week Low19.37000
iconAverage Volume0.97M
iconDividend Yield--
iconP/E Ratio--
What does the Intellia Therapeutics Inc do?
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Intellia Therapeutics Inc make?
News & Events about Intellia Therapeutics Inc.
PR Newswire
1 year ago
Thinking about buying stock in Advanced Health Intelligence, Intellia Therapeutics, Globant SA, BILL Holdings, or ONEOK? Thinking about buying stock in Advanced Health Intelligence, Intellia Therapeutics, Globant SA, BILL Holdings, or ONEOK? PR Newswire NEW YORK, June 12, 2023 NEW YORK, June 12...
Globe Newswire
1 year ago
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients (n=10), a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-upAll patients who achieved ...
TipRanks Financial Blog
1 year ago
Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV Research Report), Cardinal Health (CAH Research ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on AbbVie (ABBV Research Report), Cardinal Health...
Benzinga
1 year ago
Intellia Therapeutics, Inc.(NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002 first-in-human studies in the coming months. read more...
Fool.com Headlines
1 year ago
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.Are you looking for some growth stocks than can double in value? Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NASDAQ: NTLA) and Rivian Automotive(NASDAQ: RIVN...
Frequently Asked Questions
Frequently Asked Questions
What is Intellia Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Intellia Therapeutics Inc shares?
plus_minus_icon
How can I buy Intellia Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Intellia Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intellia Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Intellia Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Intellia Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intellia Therapeutics Inc?
plus_minus_icon
What percentage is Intellia Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intellia Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$25.17
$0.02
(0.08%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00